

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0040	
Drug name and formulations:	Desitrend® - levetiracetam coated granules in sachets (250mg, 500mg, 1000mg)	
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Equivalent to tablets or liquid
Clinical effectiveness	<i>Established licensed product</i>	Equivalent to tablets or liquid
Strength of evidence		Equivalent to tablets or liquid
Cost effectiveness or resource impact	£	Substantially more expensive than generic tablets or liquid.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	Second line, only if tablets or liquid formulation inappropriate
National guidance and priorities	<i>NICE, MTRAC</i>	N/A
Local health priorities	<i>CCG views</i>	CCGs redefined patient cohort
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	None

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	AMBER, Paediatrician initiation. For patients up to and including 16 years of age unable to swallow tablets and in whom the liquid formulation is not appropriate or tolerated.
Implementation requirements:	
Implementation monitoring:	